Proteins expressed in osteosarcoma and serum levels as prognostic factors (Q34135065)

31 July 2017

1 reference

title

Proteins expressed in osteosarcoma and serum levels as prognostic factors (English)

1 reference

31 July 2017

Trieb K

1

1 reference

31 July 2017

Kotz R

series ordinal

2

1 reference

31 July 2017

publication date

1 January 2001

1 reference

International Journal of Biochemistry & Cell Biology

31 July 2017

published in

1 reference

31 July 2017

volume

33

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

11-17

1 reference

The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86).

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Tumor size and prognosis in aggressively treated osteosarcoma

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Primary Osteogenic Sarcoma of the Femur: A Model for the Use of Preoperative Chemotherapy in High Risk Malignant Tumors

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Cardiomyopathy after osteosarcoma treatment: a contribution to the cardiotoxicity of adriamycin

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Biochemistry of multidrug resistance mediated by the multidrug transporter

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Expression of HER2/erbB-2 correlates with survival in osteosarcoma

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Alterations of the p53, Rb and MDM2 genes in osteosarcoma

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

P-glycoprotein Expression: Critical Determinant in the Response to Osteosarcoma Chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

A new puffing pattern induced by temperature shock and DNP in drosophila

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

The heat-shock response

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Heat shock proteins and the immune response

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Heat-shock protein 72 in human osteosarcoma: T-lymphocyte reactivity and cytotoxicity

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

T cell lymphoma in transgenic mice expressing the human Hsp70 gene

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

In vivo gene therapy of malignant tumours with heat shock protein-65 gene

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Escaping cell death: survival proteins in cancer

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Heat shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Do heat shock proteins have a role in breast cancer?

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Serum antibodies against the heat shock protein 60 are elevated in patients with osteosarcoma

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

Osteogenic sarcoma with clinically detectable metastasis at initial presentation

1 reference

https://api.crossref.org/works/10.1016/S1357-2725(00)50066-2

7 January 2021

10.1016/S1357-2725(00)00066-2

Identifiers

DOI

1 reference

31 July 2017

1 reference